Skip to main content
SpringerLink
Log in

The Target Concentration Approach to Clinical Drug Development

  • Leading Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sheiner LB. The intellectual health of clinical drug evaluation. Clin Pharmacol Ther 1991; 50: 4–9

    Article  PubMed  CAS  Google Scholar 

  2. Peck CC. Clinical new drug development: how golden are the eggs? Boerhaave Professorship Inaugural Lecture, Leiden University, The Netherlands, 25 Mar 1994

  3. Breimer DD. The relevance of the application of PK/PD modelling concepts. Keynote lecture, 2nd International Symposium on Measurement and Kinetics of In Vivo Drug Effects: 1994 Apr 14–16; Leiden, The Netherlands

  4. Peck CC, Barr WH, Benet LZ, et al. Opportunities for the integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. Clin Pharmacol Ther 1992; 51: 465–73

    Article  PubMed  CAS  Google Scholar 

  5. Sheiner LB, Tozer TN. Clinical pharmacokinetics: the use of plasma concentrations of drugs. In: Melmon KL, Morelli HF, editors. Clinical pharmacology: basic principles of therapeutics. New York: Macmillan; 1978: Chap. 3, 71–109

    Google Scholar 

  6. Collins JM, Grieshaber CK, Chabner BA. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 1990; 82: 1321–6

    Article  PubMed  CAS  Google Scholar 

  7. Holford NHG, Williams PEO, Muirhead GJ, et al. Population pharmacodynamics of romazarit. Br J Clin Pharmacol 1995; 39: 313–20

    Article  PubMed  CAS  Google Scholar 

  8. Vozeh S, Kewitz G, Perruchoud A, et al. Theophylline serum concentrations and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered theophylline. Am Rev Respir Dis 1982; 125: 181–4

    PubMed  CAS  Google Scholar 

  9. Holford NHG, Black P, Briant R, et al. Theophylline target concentration in severe airways obstruction — 10 or 20 mg/L? A randomised concentration-controlled trial. Clin Pharmacokinet 1993; 25: 495–505

    Article  PubMed  CAS  Google Scholar 

  10. Holford NHG, Hashimoto Y, Sheiner LB. Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction. Population analysis of a randomised concentration controlled trial. Clin Pharmacokinet 1993; 25: 506–15

    Article  PubMed  CAS  Google Scholar 

  11. Sanathan L, Peck CC. The randomized concentration-controlled trial: an evaluation of its sample size efficiency. Controlled Clin Trials 1991; 12: 780–94

    Article  Google Scholar 

  12. Levy G. Concentration-controlled versus concentration-defined trials. Clin Pharmacol Ther 1993; 53: 385

    Article  PubMed  CAS  Google Scholar 

  13. Levy G. Rebuttal: Concentration-controlled versus concentrationdefined trials. Clin Pharmacol Ther 1993; 53: 387

    Article  Google Scholar 

  14. Peck CC. Reply: Concentration-controlled versus concentrationdefined trials. Clin Pharmacol Ther 1993; 53: 385–7

    Article  Google Scholar 

  15. Endrenyi L, Zha J. Comparative efficiencies of randomized concentration- and dose-controlled trials. Clin Pharmacol Ther 1994; 56: 331–8

    Article  PubMed  CAS  Google Scholar 

  16. Levy G, Ebling WF, Forrest A. Concentration- or effect-controlled trials with sparse data. Clin Pharmacol Ther 1994; 56: 1–8

    Article  PubMed  CAS  Google Scholar 

  17. Holford NHG, Peck CC. Population pharmacodynamics and drug development. In: Van Boxtel C, Holford NHG, Danhof M, editors. The in vivo study of drug action. Amsterdam: Elsevier; 1992: 401–13

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Clinical Pharmacology, University of Auckland, Private Bag 92019, Auckland, New Zealand

    Nicholas H. G. Holford

Authors
  1. Nicholas H. G. Holford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas H. G. Holford.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holford, N.H.G. The Target Concentration Approach to Clinical Drug Development. Clin-Pharmacokinet 29, 287–291 (1995). https://doi.org/10.2165/00003088-199529050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199529050-00001

Keywords

Search

Navigation